Invasive Aspergillus niger complex infections in a Belgian tertiary care hospital  by Vermeulen, E. et al.
Invasive Aspergillus niger complex infections
in a Belgian tertiary care hospital
E. Vermeulen1, J. Maertens1,2, P. Meersseman1,2,
V. Saegeman1,2, L. Dupont1,2 and K. Lagrou1,2
1) Catholic University of Leuven and 2) University Hospitals Leuven, Leuven,
Belgium
Abstract
The incidence of invasive infections caused by the Aspergillus niger
species complex was 0.043 cases/10 000 patient-days in a Belgian
university hospital (2005–2011). Molecular typing was performed
on six available A. niger complex isolates involved in invasive
disease from 2010 to 2011, revealing A. tubingensis, which has
higher triazole minimal inhibitory concentrations, in ﬁve out of six
cases.
Keywords: Aspergillosis, Aspergillus niger, Aspergillus niger infection,
drug resistance, fungal, Invasive pulmonary aspergillosis
Original Submission: 2 July 2013; Revised Submission: 28
August 2013; Accepted: 11 September 2013
Editor: E. Roilides
Article published online: 4 November 2013
Clin Microbiol Infect 2014; 20: O333–O335
10.1111/1469-0691.12394
Corresponding author: K. Lagrou, University Hospitals Leuven,
Herestraat 49, 3000 Leuven, Belgium
E-mail: katrien.lagrou@uzleuven.be
Aspergilli are ubiquitous airborne fungi, which can cause both
allergic syndromes and opportunistic invasive infections.
Although invasive aspergillosis (IA) is caused by Aspergillus
fumigatus in most cases [1], the emergence of IA caused by
non-fumigatus species was reported in the early 2000s [2,3].
Nevertheless, A. niger complex continued to be considered of
low virulence, because of its low association with IA despite
frequent isolation, compared with other Aspergilli [4]. In two
TRANSNET cohort studies, the 1-year cumulative incidence of
A. niger complex IA was 0.048% and 0.16% in, respectively,
solid organ transplantation (SOT) patients and haematopoietic
stem cell transplant recipients [5,6]. Species-dependent differ-
ences in antifungal susceptibility are described among the
species constituting the A. niger complex [7]. The species
distribution in IA is therefore relevant for patient management.
Black Aspergilli from clinical samples (irrespective of their
clinical relevance) were shown to represent a variety of
species, mainly A. amawori (55.6%) and A. tubingensis (17.8%)
[7]. To our knowledge, molecular typing of A. niger complex
isolates from patients with IA was performed in only one
study, reporting two species involved in 19 cases: A. niger
(68.4%) and A. tubingensis (31.6%) [8]. The aim of this
retrospective study was to study the incidence of A. niger
complex IA in our centre, a 1950-bed tertiary care hospital,
and to identify the causative species.
Through the laboratory information software, we listed all
patients with A. niger complex cultured from a clinical sample,
from January 2005 through to December 2011. Patients with
IA were identiﬁed by revision of their medical ﬁles, laboratory
results and pathology data. Cases were categorized according
to the revised EORTC-MSG consensus deﬁnitions of proven
or probable invasive fungal disease [9] and the deﬁnition of
putative IA in ICU patients [10]. In 2005–2011, 160 clinical
specimens from 129 patients yielded A. niger complex (77 men;
mean age 53 years, range 1–87). Most isolates (86/160, 53.7%)
were judged to be non-relevant; 31/160 (19.4%) isolates
represented otomycosis; ﬁve isolates were yielded from
allergic bronchopulmonary aspergillosis patients (3.1%). The
remaining 38 isolates (23.7%) were cultured from 16 IA
patients. Patients with IA had a higher number of A. niger
complex cultures (2.4 positive cultures/patient, range 1–9),
compared with patients without IA (1.1/patient, range 1–3)
(p < 0.001). Table 1 summarizes the characteristics of patients
with A. niger complex IA. Three patients had a mixed infection
(simultaneous isolation) with non-Aspergillus moulds, but
relevance of the Aspergillus isolate was always demonstrated
by positive serum galactomannan levels. One patient had a
mixed infection with A. ﬂavus. Four patients had breakthrough
A. niger complex infections while on voriconazole therapy
initiated for A. fumigatus IA (n = 3) or culture-negative IA
(n = 1). In these patients, A. niger complex was cultured,
respectively, 10, 39, 72 and 102 days after initiation of
voriconazole, with increasing galactomannan levels. The
remaining 12 patients did not have exposure to mould-active
antifungals in the 6 months prior to their IA episode. The 6-
week survival rate was 62.5%. Mortality was higher in
haematology and intensive care patients (5/7, 71%) compared
with lung transplantation and COPD patients (1/9, 11%).
The incidence of A. niger complex IA was 0.043 cases/
10 000 patient-days in 2005–2011. The mean incidence of
0.023/10 000 patient-days from 2005 to 2008 increased to
0.095/10 000 patient-days in 2011 (Spearman correlation
0.73), but this rise was not statistically signiﬁcant (p 0.06)
(Fig. 1). As the incidence is calculated for culture-positive
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases
RESEARCH NOTE MYCOLOGY
episodes, these ﬁgures are probably still an underestimation of
the real incidence.
Since the end of 2010, the microbiology laboratory
routinely collects one fungal isolate from each patient with
Aspergillus disease. Six isolates from six different patients (case
11–16, see Table 1) with invasive A. niger complex infection
identiﬁed in our retrospective study were stored at 80°C.
Fresh subcultures of these strains were submitted to sequenc-
ing of the b-tubulin gene [11] and susceptibility testing (CLSI
protocol M38-A2) [12]. The epidemiological cut-off values
(ECV) for itraconazole (2 mg/L), voriconazole (2 mg/L) and
posaconazole (0.5 mg/L) were applied [13]. Five out of six
cases were attributable to a single species, A. tubingensis, which
is known to have higher triazole minimal inhibitory concen-
trations (MICs) [7]. Susceptibility testing of these ﬁve isolates
indeed revealed elevated MICs for itraconazole (range 4–
8 mg/L); MICs for voriconazole and posaconazole mostly
equalled the ECV (voriconazole MIC, range 1–2 mg/L; posa-
conazole, 0.5–1 mg/L). The only isolate with itraconazole MIC
<2 mg/L was identiﬁed as A. foetidus (case 13). The A. tubing-
ensis isolates were cultured from patients from different
wards. Seasonal variation was observed in the number of
A. niger complex isolates cultured, with a consistent drop in
winter and spring (December through to May), as previously
described [6]. This would not be observed if an in-hospital
source of conidia was responsible [14]. In addition to the
A. niger complex isolates cultured, all patients had additional
microbiological evidence for IA, excluding contamination
(galactomannan positivity or direct microscopy of specimen
with visualization of hyphae).
We described 16 A. niger complex IA cases from a single
centre, in a 7-year period. Compared with the TRANSNET
study, which typed 19 A. niger complex IA isolates from 24
transplant centres throughout the United States in a 5-year
period [8], this number is remarkable. A. tubingensis is the
pathogen involved in ﬁve out of six cases since November
2010. Higher triazole MICs in A. tubingensis makes both
environmental and in-patient selection (breakthrough infec-
tions) plausible. It is possible that triazole-resistant A. tubing-
ensis strains are selected in the environment because of the
widespread use of agricultural fungicides, in a similar way to
resistant A. fumigatus [15]. An environmental surveillance for
resistant Aspergilli, conducted by outdoor air sampling on
selective itraconazole- or voriconazole-containing agars (per-
formed June-September 2012) revealed the presence of
resistant A. tubingensis, but no other resistant species belonging
TABLE 1. Characteristics of patients with invasive Aspergillus niger complex infections, University Hospitals Leuven (January 2005
to December 2011)
Case Age Sex Underlying condition A. niger invasive aspergillosisa Samplec Therapy 6-week survival
1 51 F Polytrauma, drug-induced
agranulocytosis
Probable BAL Caspofungin Survived
2 60 F Lung transplantation Probable, voriconazole-breakthrough infection Sputum Posaconazole Survived
3 59 F AML Probable, mixed infection with Rhizopus pusillis BASP Posaconazole + L-AMB Died
4 29 F Lung transplantation Proven Lung biopsy Voriconazole + aerosole Survived
5 62 F AML Probable, mixed infection with Lichtheimia spp. BASP – Died
6 48 M COPD/emphysema Proven Lung biopsy Itraconazole + surgery Survived
7 52 F Lung transplantation Probable, mixed infection with A. ﬂavus BAL Voriconazole + aerosole Survived
8 40 F Lung transplantation Proven Lung biopsy Voriconazole + aerosole Survived
9 79 M COPD Autopsy-proven, voriconazole-breakthrough infection BASP – Died
10 69 M AML HSCT Probable, mixed infection with S. apiospermum BASP Voriconazole Died
11 45 M Pancreatitis Proven, voriconazole-breakthrough Biopsy abdomend – Died
12 57 M COPD/emphysema Putative, therapy failureb on voriconazole BAL L-AMB + caspofungin Survived
13 52 M AML Probable Sputum – Died
14 52 M Lung transplantation Probable BAL Voriconazole Survived
15 80 M Hodgkin lymphoma Proven osteomyelitis Biopsy humerus Voriconazole + surgery Survived
16 65 M COPD Putative, voriconazole-breakthrough BAL Voriconazole (continued) Survivedf
aAll pulmonary aspergillosis, except case 15.
bRadiological progression of CT lesions, clinical deterioration and unchanged high BAL galactomannan levels (index up to 11.7).
cClinical sample type from which A. niger complex was cultured. If multiple isolates were cultured, this refers to the most relevant positive sample (biopsy > BAL > BASP > spu-
tum).
dMost relevant pulmonary sample: BASP.
eAerosolized conventional amphotericin B.
fDied at week 15. AML, acute myeloid leukaemia; BASP, bronchial aspirate; COPD, chronic obstructive pulmonary disease; HSCT, haematopoietic stem cell transplantation; L-
AMB, liposomal amphotericin B.
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FIG. 1. Increasing incidence of invasive Aspergillus niger complex
infections in University Hospitals Leuven, 2005–2011.
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to the A. niger complex, throughout the environment in
Belgium (data not shown). It is a limitation of our study that
only six isolates were fully typed as the isolates from January
2005 to October 2010 were not stored. As a consequence, we
cannot resolve whether the recent A. niger complex infections
are attributable to a true emergence of A. tubingensis or
A. tubingensis infections were already present in 2005–2010.
This is a single-centre study; therefore, the presented data
might reﬂect the local epidemiology. The virulence and
epidemiology of A. tubingensis need further research.
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